Pulmonary Disease Doctors in Georgetown, KY - Medicare Status, Address, Contact

1 Pulmonary Disease doctors found. Showing 1 - 1

Firas A Koura, M.D.
Internal Medicine - Pulmonary Disease
Medicare: Accepting Medicare Assignments
Practice Location: 1138 Lexington Rd Ste 230, Georgetown, KY 40324
Phone: 502-570-3706 Fax: 502-570-3760

News Archive

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

Researchers confirm new therapeutic target for myelodysplastic syndrome

A research group from Kumamoto University, Japan analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of the transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered a tumor suppressor.

Recent releases in Global Health

The Infectious Diseases Center for Global Health Policy's "Science Speaks" blog examines U.S. Global AIDS Coordinator Eric Goosby's recent address to the Conference on Retroviruses and Opportunistic Infections (CROI) where he reemphasized the Obama administration's commitment to "'maintaining, extending and increasing' the U.S. response to global AIDS." Goosby reflected on the lessons drawn from PEPFAR to date and presented components of the 5-year PEPFAR strategy, the blog notes.

New research opens door for development of treatments capable of stopping Alzheimer's disease

New research just out in the journal Science Translational Medicine opens the door for the development of treatments capable of stopping Alzheimer's disease (AD) before its first symptoms, that is to say before any crucial damage occurs. In fact, if AD is a devastating disorder it is also an extremely slow one; it takes more than 10 years for the first symptoms to appear making this preclinical period (pre-symptoms) the ideal time to intervene.

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.

Pulmonary Disease Doctors in Georgetown, KY Accepting Medicare